Revakinagene for MacTel: Is the Benefit Worth the Cost? - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Revakinagene for MacTel: Is the Benefit Worth the Cost?

High-cost therapies have consistently been approved for conditions with significant unmet medical need, particularly when irreversible loss of function, such as blindness, is imminent. Decisions are based not only on clinical efficacy but also on prevention of long-term societal costs and preservation of patient autonomy. Therefore, it is our opinion that the benefit of revakinagene is worth the premium cost.

  • By

  • Michael Colucciello, MD

  • Martin Friedlander, MD, PhD

  • Kristin Raming, MD

  • September 1, 2026

  • 15 min

Share

Original Source(s)

Revakinagene for MacTel: Is the Benefit Worth the Cost?

  • by Michael Colucciello, MD, Martin Friedlander, MD, PhD, Kristin Raming, MD

  • September 1, 2026

Related Content

Chinese Trial Validates Scleral Lenses

Large Chinese trial confirms strong visual outcomes with four-zone scleral lenses for irregular corneas

  • August 28, 2026

  • 3 min
Vitrectomy Linked to Higher CME Risk

Large US database study suggests previous pars plana vitrectomy may substantially increase likelihood of pseudophakic cystoid macular edema

  • August 26, 2026

  • 3 min
Is This the New Norm?: <br>Is Overcomplicating Ortho-k the New Normal?</br>